Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results

Preventive Medicine

Volumn 118, Issue , 2019, Pages 44-50

  Castle, Philip E ^a   Xie, Xianhong ^a   Xue, Xiaonan ^a   Poitras, Nancy E ^b   Lorey, Thomas S ^b   Kinney, Walter K ^b   Wentzensen, Nicolas ^c   Strickler, Howard D ^a   Burger, Emily A ^d   Schiffman, Mark ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cervical precancer; Cytology; Human papillomavirus (HPV); Screening; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGE; ARTICLE; BLACK PERSON; CALIFORNIA; CANCER GRADING; CANCER RISK; CANCER SCREENING; CAUCASIAN; ETHNIC DIFFERENCE; FEMALE; HISPANIC; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; YOUNG ADULT; EARLY CANCER DIAGNOSIS; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX TUMOR; VACCINATION;

ADULT; CALIFORNIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 85054796006     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2018.10.001     Document Type: Article

References (41)

1. Arbyn, M., Anttila, A., Jordan, J., et al. European guidelines for quality assurance in cervical cancer screening. Second edition–summary document. Ann. Oncol. 21:3 (2010 Mar), 448–458.
2. Baldur-Felskov, B., Dehlendorff, C., Munk, C., Kjaer, S.K., Early impact of human papillomavirus vaccination on cervical neoplasia–nationwide follow-up of young Danish women. J. Natl. Cancer Inst., 106(3), 2014 Mar, djt460.
3. Carreon, J.D., Sherman, M.E., Guillen, D., et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int. J. Gynecol. Pathol. 26:4 (2007 Oct), 441–446.
4. Castle, P.E., Stoler, M.H., Solomon, D., Schiffman, M., The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses:an ALTS report. Am. J. Clin. Pathol. 127:5 (2007 May), 805–815.
5. Castle, P.E., Solomon, D., Saslow, D., Schiffman, M., Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States. Cancer 113:10 Suppl (2008 Nov 15), 3031–3035.
6. Castle, P.E., Sideri, M., Jeronimo, J., Solomon, D., Schiffman, M., Risk assessment to guide the prevention of cervical cancer. J. Low. Genit. Tract Dis. 12:1 (2008 Jan), 1–7.
7. Crowe, E., Pandeya, N., Brotherton, J.M., et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ, 348, 2014 Mar 4, g1458, 10.1136/bmj.g1458.:g1458.
8. Drolet, M., Benard, E., Boily, M.C., et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect. Dis. 14 (2015 Mar 2), 10–3099.
9. Eversole, G.M., Moriarty, A.T., Schwartz, M.R., et al. Practices of participants in the college of american pathologists interlaboratory comparison program in cervicovaginal cytology, 2006. Arch. Pathol. Lab. Med. 134:3 (2010 Mar), 331–335.
10. Haupt, R.M., Wheeler, C.M., Brown, D.R., et al. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int. J. Cancer 129:11 (2011 Dec 1), 2632–2642.
11. Katki, H.A., Schiffman, M., Castle, P.E., et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J. Low. Genit. Tract Dis. 17:5 Suppl 1 (2013 Apr), S28–S35.
12. Katki, H.A., Schiffman, M., Castle, P.E., et al. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. J. Low. Genit. Tract Dis. 17:5 Suppl 1 (2013 Apr), S36–S42.
13. Katki, H.A., Schiffman, M., Castle, P.E., et al. Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results. J. Low. Genit. Tract Dis. 17:5 Suppl 1 (2013 Apr), S43–S49.
14. Kavanagh, K., Pollock, K.G., Cuschieri, K., et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect. Dis. 17:12 (2017 Dec), 1293–1302.
15. Kim, J.J., Burger, E.A., Sy, S., Campos, N.G., Optimal cervical cancer screening in women vaccinated against human papillomavirus. J. Natl. Cancer Inst., 109(2), 2016 Oct 18, djw216.
16. Kjaer, S.K., Sigurdsson, K., Iversen, O.E., et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev. Res. (Phila.) 2:10 (2009 Oct), 868–878.
17. Kyrgiou, M., Athanasiou, A., Paraskevaidi, M., et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ, 354, 2016 Jul 28, i3633, 10.1136/bmj.i3633.:i3633.
18. Lehtinen, M., Paavonen, J., Wheeler, C.M., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13:1 (2012 Jan), 89–99.
19. Markowitz, L.E., Dunne, E.F., Saraiya, M., Lawson, H.W., Chesson, H., Unger, E.R., Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm. Rep. 56:RR-2 (2007 Mar 23), 1–24.
20. Merck, Gardasil package insert. U S food and drug administration. [cited 2018 Mar 29]; Available from: URL https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm111263.pdf, 2011.
21. Munoz, N., Bosch, F.X., de Sanjose, S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:6 (2003 Feb 6), 518–527.
22. Munoz, N., Kjaer, S.K., Sigurdsson, K., et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J. Natl. Cancer Inst. 102:5 (2010 Mar 3), 325–339.
23. Palmer, T.J., McFadden, M., Pollock, K.G., et al. HPV immunisation and cervical screening–confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study. Br. J. Cancer 114:5 (2016 Mar 1), 582–589.
24. Pedersen, K., Burger, E.A., Nygard, M., Kristiansen, I.S., Kim, J.J., Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: the value of stratifying guidelines. Eur. J. Cancer 91 (2018 Mar), 68–75, 10.1016/j.ejca.2017.12.018 (Epub;%2018 Jan 12.:68-75).
25. Rambout, L., Tashkandi, M., Hopkins, L., Tricco, A.C., Self-reported barriers and facilitators to preventive human papillomavirus vaccination among adolescent girls and young women: a systematic review. Prev. Med. 58 (2014 Jan), 22–32, 10.1016/j.ypmed.2013.10.009 (Epub;%2013 Oct 28.:22-32).
26. Sasieni, P., Castanon, A., Cuzick, J., Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ, 339, 2009 Jul 28, b2968, 10.1136/bmj.b2968.:b2968.
27. Sasieni, P., Castanon, A., Landy, R., et al. Risk of preterm birth following surgical treatment for cervical disease: executive summary of a recent symposium. BJOG 123:9 (2016 Aug), 1426–1429.
28. Schiffman, M., Rodriguez, A.C., Heterogeneity in CIN3 diagnosis. Lancet Oncol. 9:5 (2008 May), 404–406.
29. Schiffman, M., Castle, P.E., Jeronimo, J., Rodriguez, A.C., Wacholder, S., Human papillomavirus and cervical cancer. Lancet 370:9590 (2007 Sep 8), 890–907.
30. Scott, D.R., Hagmar, B., Maddox, P., et al. Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom. Cancer 96:1 (2002 Feb 25), 14–20.
31. Silverberg, M.J., Leyden, W.A., Lam, J.O., et al. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study. Lancet Child Adolesc. Health 2:10 (2018 Oct), 707–714.
32. Solomon, D., Schiffman, M., Tarone, R., Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J. Natl. Cancer Inst. 93:4 (2001 Feb 21), 293–299.
33. Solomon, D., Davey, D., Kurman, R., et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 287:16 (2002 Apr 24), 2114–2119.
34. Stokley, S., Jeyarajah, J., Yankey, D., et al. Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014–United States. MMWR Morb. Mortal. Wkly Rep. 63:29 (2014 Jul 25), 620–624.
35. Stoler, M.H., Ronnett, B.M., Joste, N.E., Hunt, W.C., Cuzick, J., Wheeler, C.M., The interpretive variability of cervical biopsies and its relationship to HPV status. Am. J. Surg. Pathol. 39:6 (2015 Jun), 729–736.
36. Tainio, K., Athanasiou, A., Tikkinen, K.A.O., et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ, 360, 2018 Feb 27, k499 (k499).
37. U.S. Preventive Service Task Force, Draft evidence review for cervical cancer: screening. U S preventive service task force. [cited 2017 Dec 9]; Available from: URL https://www.uspreventiveservicestaskforce.org/Page/Document/draft-evidence-review/cervical-cancer-screening2, 2017.
38. Walboomers, J.M., Jacobs, M.V., Manos, M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:1 (1999 Sep), 12–19.
39. Wright, T.C. Jr., Cox, J.T., Massad, L.S., Twiggs, L.B., Wilkinson, E.J., 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 287:16 (2002 Apr 24), 2120–2129.
40. Wright, T.C. Jr., Massad, L.S., Dunton, C.J., Spitzer, M., Wilkinson, E.J., Solomon, D., 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J. Low. Genit. Tract Dis. 11:4 (2007 Oct), 223–239.
41. Wright, T.C. Jr., Massad, L.S., Dunton, C.J., Spitzer, M., Wilkinson, E.J., Solomon, D., 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J. Low. Genit. Tract Dis. 11:4 (2007 Oct), 201–222.